241. 高チロシン血症1型 Hypertyrosinemia type I Clinical trials / Disease details
臨床試験数 : 14 / 薬物数 : 7 - (DrugBank : 1) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 5
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02750345 (ClinicalTrials.gov) | March 2016 | 21/4/2016 | Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1) | A Three-Period Crossover Study to Determine the Bioequivalence of Two Oral Formulations Containing Nitisinone 10 mg Compared to Reference Formulation Orfadin In Healthy Subjects Under Fasting Conditions | Hereditary Tyrosinemia, Type I | Drug: Nitisinone;Drug: Nitisinone Baked Tablet;Drug: Orfadin | Cycle Pharmaceuticals Ltd. | Parexel | Completed | 18 Years | 55 Years | All | 24 | Phase 1 | South Africa |